Sep. 24 at 5:14 PM
UBS reiterated
$MDGL at Buy-
$523-High Conviction Call and said, we think mgmt sounds upbeat on #MASH market dynamics, highlights durable large opportunity in the growing MASH market
Reiterate high conviction call in
$MDGL as a commercial biotech story where we still see significant upside potential to valuation on Rezdiffra launch trajectory in the near & long-term ... We think mgmt continues to sound upbeat on Rezdiffra's profile, the launch, and the long-term opportunity. Notably, we think mgmt sounds confident in continued patient demand amidst the launch of sema & upbeat on conversations with payors.
$NVO $IVA $VKTX $ALGS